IRAK4-IN-19
IRAK4-IN-19 is a potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 value of 4.3 nM. IRAK4-IN-19 can inhibit LPS-induced IL23 production in THP and DC cells, and stop arthritis development in arthritis rats. IRAK4-IN-19 can be used for researching arthritis disease.
For research use only. We do not sell to patients.
- CAS No.: 3032075-32-1
- Formula: C25H26F2N8O
- Molecular Weight:492.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IRAK4 4.3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.82 μM
Compound: 39
|
Induction of PAD activity against human A549 cells
Induction of PAD activity against human A549 cells
|
[PMID: 35863718] |
| Dendritic cell | IC50 |
0.22 μM
Compound: 39
|
Antiinflammatory activity against human dendritic cells assessed as inhibition of LPS induced IL-23 production
Antiinflammatory activity against human dendritic cells assessed as inhibition of LPS induced IL-23 production
|
[PMID: 35863718] |
| THP-1 | IC50 |
0.23 μM
Compound: 39
|
Antiinflammatory activity against human THP-1 cells assessed as inhibition of LPS induced IL-23 production
Antiinflammatory activity against human THP-1 cells assessed as inhibition of LPS induced IL-23 production
|
[PMID: 35863718] |
IRAK4-IN-19 (compound 39) has inhibitory activity against LPS-induced IL23 in THP and DC with IC50s of 0.23 and 0.22 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
IRAK4-IN-19 (1 mg/kg for IV, 5 mg/kg for PO, single dosage) exhibits a favorable pharmacokinetics profile[1].
IRAK4-IN-19 (5, 15, 45 and 75 mg/kg) exhibits good efficacy in an acute mouse model for the IL-1β induced IL-6 expression, with 64% inhibition at 75 mg/kg dose, 37% inhibition at 45 mg/kg dose, 16% inhibition at 15 mg/kg dose and 9% inhibition at 5 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rats[1]
-
Dosage:30 mg/kg
-
Administration:twice daily for 21 days
-
Result:Completely stopped arthritis development in arthritis rats at 30 mg/kg.
-
Animal Model:Rats[1]
-
Dosage:1 mg/kg, 5 mg/kg
-
Administration:IV and PO, single dosage
-
Result:Exhibited a favorable pharmacokinetics profile with a clearance of 6 mL/min/kg and oral bioavailability of 43%.
Chemical Information
-
CAS No. 3032075-32-1
-
Molecular Weight 492.52
-
Formula C25H26F2N8O
-
SMILES
CC(N1N=CC2=C1C=C(NC(N=C3C=C4)=NC(N[C@H]5[C@@H](C(N)=O)[C@@H]6C=C[C@H]5C6)=C3N4C(F)F)C=C2)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IRAK4-IN-19 Related Classifications
HY-150733 Related Classifications
Powered by Bioz